Innate immune cells in chimeric antigen receptor therapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has transformed cancer treatment, especially for blood cancers.
• Significant challenges hinder CAR-T cell efficacy in solid tumors, including toxicity and manufacturing costs.
• Alternative immune effector cells are being explored to overcome these limitations.

Purpose of the Study:

• To review the biological basis and clinical potential of CAR-engineered innate immune cells.
• To highlight advancements in using innate immune cells for solid tumor treatment.
• To discuss future strategies for next-generation CAR-based therapies.

Main Methods:

• Review of preclinical and clinical studies on CAR-engineered innate immune cells.
• Analysis of the advantages of innate immune cells (NK cells, macrophages, etc.) over T cells.
• Exploration of combinatorial strategies for enhanced efficacy.

Main Results:

• Innate immune cells offer advantages like lower graft-versus-host disease risk and suitability for off-the-shelf platforms.
• CAR-engineered innate cells demonstrate potential for improved tumor infiltration and reduced toxicity.
• Preclinical and early clinical data support the viability of these novel CAR-based approaches.

Conclusions:

• CAR-engineered innate immune cells represent a promising alternative to CAR-T cells for solid tumor treatment.
• Overcoming challenges in solid tumors may be achievable through innate immune cell-based CAR therapies.
• Future research should focus on combinatorial strategies and optimizing CAR-innate cell platforms.